IRLAB Therapeutics AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0012675361
SEK
2.35
0.15 (6.59%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -80.51%, its profits have risen by 13.5%
2

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 199 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.50

stock-summary
Return on Equity

-169.55%

stock-summary
Price to Book

3.68

Revenue and Profits:
Net Sales:
20 Million
(Quarterly Results - Jun 2025)
Net Profit:
-32 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.04%
0%
-15.04%
6 Months
-65.45%
0%
-65.45%
1 Year
-80.29%
0%
-80.29%
2 Years
-63.26%
0%
-63.26%
3 Years
-93.77%
0%
-93.77%
4 Years
-94.87%
0%
-94.87%
5 Years
-94.29%
0%
-94.29%

IRLAB Therapeutics AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
144.04%
EBIT Growth (5y)
3.39%
EBIT to Interest (avg)
-41.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.36
Sales to Capital Employed (avg)
0.65
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
2.69%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.24
EV to EBIT
-2.51
EV to EBITDA
-2.63
EV to Capital Employed
-33.71
EV to Sales
3.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 343.18% vs -89.72% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.00% vs -529.63% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.50",
          "val2": "4.40",
          "chgp": "343.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.70",
          "val2": "-28.50",
          "chgp": "20.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.00",
          "val2": "5.60",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.30",
          "val2": "-34.00",
          "chgp": "5.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,220.10%",
          "val2": "-6,793.80%",
          "chgp": "557.37%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1,559.65% vs -90.67% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 53.26% vs -56.79% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.60",
          "val2": "5.70",
          "chgp": "1,559.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-87.80",
          "val2": "-175.80",
          "chgp": "50.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.50",
          "val2": "0.20",
          "chgp": "5,150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-83.10",
          "val2": "-177.80",
          "chgp": "53.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-976.70%",
          "val2": "-31,724.60%",
          "chgp": "3,074.79%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
19.50
4.40
343.18%
Operating Profit (PBDIT) excl Other Income
-22.70
-28.50
20.35%
Interest
7.00
5.60
25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-32.30
-34.00
5.00%
Operating Profit Margin (Excl OI)
-1,220.10%
-6,793.80%
557.37%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 343.18% vs -89.72% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 5.00% vs -529.63% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
94.60
5.70
1,559.65%
Operating Profit (PBDIT) excl Other Income
-87.80
-175.80
50.06%
Interest
10.50
0.20
5,150.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-83.10
-177.80
53.26%
Operating Profit Margin (Excl OI)
-976.70%
-31,724.60%
3,074.79%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 1,559.65% vs -90.67% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 53.26% vs -56.79% in Dec 2023

stock-summaryCompany CV
About IRLAB Therapeutics AB stock-summary
stock-summary
IRLAB Therapeutics AB
Pharmaceuticals & Biotechnology
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Company Coordinates stock-summary
Company Details
Arvid Wallgrens Backe 20 , GOETEBORG None : 413 46
stock-summary
Tel: 46 31 757380046 730 757701
stock-summary
Registrar Details